rss icon

KALAMAZOO — Armune BioScience Inc.’s sale to Madison, Wis.-based Exact Sciences Corp. reinforces the reality that some West Michigan-based life sciences firms will have to move out of the region to grow.

Published in Health Biz

KALAMAZOO — Armune BioScience Inc.’s sale to a Wisconsin company provides another exit for investors that generates returns they can use in future deals for life sciences startups in Michigan.

Published in Health Biz

 

The availability of scientific and executive management talent and the access to later-stage investment capital remain major issues for Michigan’s life sciences industry.

Published in Life Sciences

At some point in the coming months, Mark Gurney and directors at Tetra Discovery Partners LLC will decide which road to travel into the future for their company.

Published in Life Sciences
Sunday, 06 March 2016 13:53

MiBiz Growth Report: March 7, 2016

Here is the MiBiz Growth Report for March 7, 2016.

Published in Economic Development

Armune Bioscience Inc. raised nearly $9.1 million in a capital round to support further commercialization of a blood test to screen for prostate cancer.

Published in In the News

An agreement with a Canadian company will significantly expand sales and marketing efforts for Armune Bioscience Inc. and its new blood test for prostate cancer that hit the market this year. Under the co-marketing deal, Quebec City-based Aeterna Zenteris Inc. will market Armune’s Apifiny blood test alongside its own products as it meets with health systems and large medical groups across the U.S. 

Published in Health Biz

With the additional $20 million it seeks to raise, Armune BioScience Inc. hopes to drive growth as well as research new applications for the blood test it developed to diagnose prostate cancer.

Venture capital investing in Michigan got off to a strong start in 2014, as the amount invested in the first quarter reached the highest value in 15 years.

Published in Finance

After naming a new CEO and CFO last month and closing on the first round of a $2.5 million capital raise, Armune BioScience Inc. aims to move into the marketplace this spring with a new-generation blood test for men suspected of having prostate cancer.

Published in Life Sciences
Page 1 of 2

Breaking News

May 2018
S M T W T F S
29 30 1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31 1 2

Follow MiBiz